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Abstract
Background: Chronic Obstructive Pulmonary Disease is one of the commonest respiratory diseases in the United
Kingdom, accounting for 10 % of unplanned hospital admissions each year. Nearly a third of these admitted
patients are re-admitted to hospital within 28 days of discharge. Whilst there is a move within the NHS to ensure
that people with long-term conditions receive more co-ordinated care, there is little research evidence to support
an optimum approach to this in COPD. This study aims to evaluate the effectiveness of introducing standardised
packages of care i.e. care bundles, for patients with acute exacerbations of COPD as a means of improving hospital
care and reducing re-admissions.
Methods / Design: This mixed-methods evaluation will use a controlled before-and-after design to examine the
effect of, and costs associated with, implementing care bundles for patients admitted to hospital with an acute
exacerbation of COPD, compared with usual care. It will quantitatively measure a range of patient and organisational
outcomes for two groups of hospitals - those who deliver care using COPD care bundles, and those who deliver care
without the use of COPD care bundles. These care bundles may be provided for patients with COPD following
admission, prior to discharge or at both points in the care pathway. The primary outcome will be re-admission to
hospital within 28 days of discharge, although the study will additionally investigate a number of secondary outcomes
including length of stay, total bed days, in-hospital mortality, costs of care and patient / carer experience. A series of
nested qualitative case studies will explore in detail the context and process of care as well as the impact of COPD
bundles on staff, patients and carers.
Discussion: The results of the study will provide information about the effectiveness of care bundles as a way of
managing in-hospital care for patients with an acute exacerbation of COPD. Given the number of unplanned
hospital admissions for this patient group and their rate of subsequent re-admission, it is hoped that this
evaluation will make a timely contribution to the evidence on care provision, to the benefit of patients, clinicians,
managers and policy-makers.
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Background
Epidemiology of COPD
Chronic Obstructive Pulmonary Disease (COPD) is one
of the most common respiratory diseases in the United
Kingdom [1] (UK). It is estimated that the prevalence of
COPD in the UK is over 3 million, of which only about
900,000 cases have been diagnosed [2]. The majority of
people with COPD also have other medical problems;
most commonly ischaemic heart disease which occurs in
some 25 % of patients [3]. Many people discharged from
hospital after an acute exacerbation of chronic obstruct-
ive pulmonary disease (AECOPD) also report feelings of
depression (64 %) and anxiety (40 %). This multi-
morbidity means that managing patients’ healthcare
needs is challenging [4–6].
COPD and unplanned hospital admissions
COPD accounts for 10 % of unplanned hospital medical
admissions – totalling over 90,000 annually in the UK
[1]. Nearly a third of these patients are re-admitted to
hospital within 28 days of discharge [7] and this propor-
tion is steadily rising, with a 2 % increase in the re-
admission rate between 2003 and 2008 [3]. During the
same time period, there has been little change in in-
hospital mortality rates; estimated at 7.5 % in
2003 and 7.7 % in 2008 [7]. As well as being an import-
ant cause of unplanned admissions, COPD is the second
most common cause of emergency admission to hospital
[2] and the fifth largest cause of re-admission [8], costing
the National Health Service (NHS) an estimated £491
million per year [9]. Indeed, the number of admissions
has increased by 50 % in the last decade and now ac-
counts for one million bed days per annum [10]. All of
these figures suggest that acute, urgent and emergency
COPD healthcare will continue to challenge the NHS
for the foreseeable future and, as such, there is consider-
able pressure on managers and clinicians to work to re-
solve the issue.
Evidence-based COPD care
Emergency admissions to hospital for long-term condi-
tions - including COPD - form part of the NHS Out-
comes Framework [11] and are the subject of a number
of admission reduction initiatives [12-14]. It has been
suggested that 10–34 % of COPD admissions could be
avoided through the implementation of evidence-based
care [7, 11]. A Royal College of Physicians Audit con-
ducted in 2003 [15] found that, on average, patients
spend 8.7 days in hospital during an admission for
COPD but also that there was wide variation in terms of
both treatment provision and outcomes amongst hospi-
tals. This disparity was particularly marked in relation to
mortality. The audit showed that a significant proportion
of the observed variability could be explained by avail-
ability and access to expert care and evidence-based in-
terventions which have, in turn, resulted in a reduced
length of stay and lower mortality [7]. This, therefore,
presents a potential opportunity to improve outcomes
for patients with COPD [3] by ensuring that their care is
consistently provided to a high standard.
COPD care bundles
One example of an evidence-based intervention is the
use of care bundles. These are a simple way of focusing
service improvement efforts on a set of defined actions
which will contribute to the achievement of a clearly
specified aim [10]. Improvement theory suggests that,
properly implemented, the use of care bundles should
enable clinical teams to concentrate on a range of meas-
urable activities and optimise certain associated out-
comes [10]. In practical terms, this should mean that
protocol-based care bundles for COPD will enable staff
to see quickly what course of action should be taken,
when and by whom, and that this will result in standard-
isation of practice in the treatment of patients. COPD
care bundles could also be an important tool in improv-
ing the quality of care, since any deviation from the
agreed care pathway can be measured easily, enabling
systemic factors that might inhibit provision of best care
to be identified and subsequently addressed.
Justification for research
Some evaluation of the effectiveness of a number of types
of care bundles [10, 16] has taken place, but there is little
UK-based evidence at present, about their impact on the
processes and outcomes of care for COPD [17, 18]. The
preliminary findings of single pilot sites in the UK indicate
that the implementation of in-patient care pathways or
bundles can improve clinical outcomes such as mortality,
hospital re-admission rates and length of hospital stay. In-
deed, a study by Hopkinson and colleagues has shown a
downward trend in 30-day re-admissions in patients with
COPD in whom a bundle approach to discharge was ap-
plied [19]. However, in order to improve outcomes for
COPD, greater understanding of clinical care, service de-
livery gains and cost-effectiveness is required. In doing so,
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more in-depth knowledge will be gained about the poten-
tial for COPD care bundles to reducing unplanned hos-
pital admissions and improve patient outcomes.
Aim
This study aims to evaluate the effectiveness of introdu-
cing standardised packages of care i.e. bundles, for pa-
tients with an acute exacerbation of COPD as a means
of improving hospital care and reducing re-admissions.
Methods
Study design
The research will use a controlled before-and-after de-
sign with nested case studies to compare the outcomes
of care following the introduction of care bundles with
usual care for patients admitted to hospital with
AECOPD. Study sites will participate in up to three
different levels of data collection and these are described
in the schematic presented in Fig. 1.
Study setting
The evaluation will be conducted in up to 40 acute hos-
pitals within England and Wales. The aim is to include a
group of hospitals who offer care to patients admitted
with COPD using a care bundle approach (i.e. imple-
mentation sites) and a broadly comparable group of hos-
pitals who deliver care for the same patient population
without the use of care bundles (i.e. comparator sites).
Inclusion and exclusion criteria
The target population for Level 1 and Level 2 participa-
tion will be acute hospitals with an emergency depart-
ment (ED) and adult respiratory in-patient care.
Hospitals outside England and Wales will be excluded.
The target population for Level 3 participation will be
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Fig. 1 Schematic representation of study design
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people over the age of 18, admitted to hospitals partici-
pating in Level 1 or Level 2 data collection where their
primary cause of admission is COPD as defined by the
International Statistical Classification of Diseases and
Related Health Problems [20] (ICD-10) using diagnostic
codes J41-J44, or carers of such individuals. This may be
a first, second or indeed a subsequent admission for that
patient during the study period, but excludes admissions
related to any form of elective treatment for COPD.
Recruitment
Identification of sites
There are two types of participating sites in the study –
implementation sites and comparator sites – and both
will be identified using similar methods. In order to
maximise the number and diversity of hospitals given
the opportunity to participate in the research, a range of
approaches will be used. These include:
 advertising calls for interest on the British
Thoracic Society (BTS) website (https://www.brit-
thoracic.org.uk/)
 advertising calls for interest on the respiratory
section of the National Institute of Health Research
(NIHR) Clinical Research Network (CRN) website
(https://www.crn.nihr.ac.uk/news/call-for-hospitals-
not-currently-using-care-bundles-for-copd-patients/)
 approaching respiratory specialists from NHS trusts
at BTS scientific meetings
 communicating calls for interest via NIHR CRN-
nominated local respiratory research leads
 communicating calls for interest via NIHR CRN
delivery managers
 generating new clinical contacts from known ones
using ‘snowballing’ techniques
 making ‘cold calls’ to major acute hospitals not
otherwise contacted
Recruitment of sites
Once a hospital has expressed their interest in taking part
in the research, they will be sent further information about
the study including a link to the NIHR CRN Portfolio
database (http://public.ukcrn.org.uk/Search/StudyDetail.
aspx?StudyID=17828), a link to the study website hosted
by the University of Bristol (http://www.bristol.ac.uk/
primaryhealthcare/researchthemes/copd/), a research
summary, the full study protocol and a copy of the BTS
COPD care bundles pilot study report [10]. Next, the hos-
pital’s status as either an implementer of COPD care bun-
dles or a comparator delivering standard care will be
determined, and the site asked to sign a formal agreement
to be a participate in the evaluation accordingly. Following
this, a member of the research team will submit the rele-
vant site-specific information (SSI) via the Integrated
Research Application System (IRAS) website (www.myre-
searchproject.org.uk/) and liaise directly with the site’s
Research & Development (R&D) team to ensure all appro-
priate permissions and approvals are in place. This will in-
clude the appointment of a local Principal Investigator
(PI) at each site to take responsibility for data collection
and patient care.
Allocation to study level and matching of sites
Eight implementation sites will be assigned to Level 2
for data collection and analysis purposes. This allocation
will depend on two conditions being met – namely, de-
livering both an admission and a discharge bundle for
COPD care and being willing to report on the Level 2
data requirements. Any remaining implementation sites
will be allocated to Level 1 participation. Eight further
sites will be selected from amongst the comparator sites
able to fulfil the same Level 2 conditions in order to
obtain eight matched implementation-comparator site
pairs. The pairs will be matched as closely as possible on
the following pre-specified criteria: number of COPD
admissions, 28-day re-admission rates and COPD mor-
tality rates.
Identification of participants
Up to ten individuals (i.e. patients who have been admit-
ted following an acute exacerbation of COPD, or their
carers) will be identified by respiratory team members as
being appropriate for participation in the study at a sam-
ple of sites chosen as Level 3 case study locations. Indi-
viduals will be selected at various stages of the COPD
patient care pathway, including the emergency depart-
ment, admissions units, and in-patients wards. This as-
sessment will take account of their health status, level of
cognition and ability to communicate easily with the re-
search team.
Recruitment of participants
Patients and their carers will be invited to take part in
the study following the procedures set out in the
International Conference on Harmonisation (ICH) good
clinical practice (GCP) guidelines (www.ich.org/), with
informed written consent being obtained prior to any
data collection. Where appropriate, individuals will be
interviewed during the period of admission, as well as
being interviewed at 30 and 90 days post-discharge, ei-
ther face-to-face or via telephone. Staff involved in an
individual patient’s care will also be invited to interview
in a similar manner and at similar time-points.
Intervention / implementation
The intervention of interest in this study is COPD care
bundles delivered as part of in-hospital patient care. In
order to encompass the full range of measures required,
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two separate care bundles were derived [10]. The first is
to be completed at the point of hospital admission and
aims to reduce length of stay and in-hospital mortality
for COPD. The second is to be completed before dis-
charge from hospital and aims to reduce re‐admissions
for COPD. Together, these two co-ordinated packages of
care comprise ten evidence-based actions which, when
successfully completed, are designed to lead to an im-
provement in the overall care for those patients admitted
to hospital with an acute exacerbation of chronic ob-
structive pulmonary disease. For the purposes of this
study, all participating hospitals who deliver some form
of care bundles i.e. implementation sites at either Level
1 or 2, will be offered a series of training and networking
opportunities in order to promote quality improvement
and to facilitate their local implementation processes.
Further details of both care bundles are provided in
Figs. 2 and 3.
Outcomes and outcome measures
The primary outcome of the evaluation is COPD re-
admission rate at 28 days, which is the proportion of
people re-admitted to hospital within 28 days of dis-
charge for an AECOPD. This will be measured using
Level 1 data from each of the participating sites. We will
calculate the mean change in 28-day re-admission rate
following the introduction of care bundles for each site,
and then compare these site level summaries between
implementation and comparator arms.
A variety of secondary outcome data will be collected
over the course of the evaluation, including:
 total number of COPD admissions
 COPD admission rate
 in-hospital mortality for COPD admissions
 length of stay for COPD admissions
 total bed days for COPD admission
 COPD re-admission rate at 90 days
 overall re-admission rate at 28 days
 total number of patients with COPD seen /
discharged from the emergency department
 total number of patients with COPD in whom
bundle used – at implementation sites only
 cost-effectiveness of COPD care bundles from an
NHS perspective
 context and process of care
 impact of the care bundles on patients, carers and
staff – at implementation sites only
Data collection
Data will be collected at each implementation site over a
minimum 24-month period – 12 months immediately
preceding the implementation of the COPD care bundle(s)
and 12 months after the start of implementation. Since
it is likely that some sites will have an implementation
phase during which their COPD care bundle(s) become
embedded into clinical practice, data will also be col-
lected during this time-period as appropriate. What-
ever the total data collection period at implementation
sites, data collected by comparator sites will reflect a
similar distribution of 12-month ‘before’ and 12-month
‘after’ calendar time-period. One implementation site
will be recruited to pilot data collection at all three
levels.
Sites will appoint appropriate people to report their
data to the research team. The frequency of the data ex-
traction will depend on the time-period that the site is
reporting for, as well as the resources available to them.
For example, if all of the data extraction is retrospective,
the hospital may choose to provide all the data in one
COPD admission care bundle
1) Ensure correct diagnosis of AECOPD with both: 
a. chest x-ray- result of chest x-ray documented in notes within 4 hours and
b. ECG-result of ECG documented in the notes within 4 hours
2) Recognise and respond to respiratory acidosis within 3 hours of admission
a. arterial blood gas within 1 hour if oxygen sats less than 94% on air or controlled oxygen
b. when pH less than 7.35 assess suitability for NIV and implement within 3 hours of admission
3) Recognition of hypoxia and correct oxygen prescription within 30 minutes of admission with target range of    
88-92%
4) Correct prescription of medication for AECOPD at admission
a. steroids prescribed and administered within 4 hours of admission when necessary
b. antibiotics prescribed and administered within 4 hours of admission where necessary
c. nebulisers prescribed and administered within 1 hour if appropriate 
5) Review by respiratory specialist (specialist nurse, doctor or physiotherapist) within 24 hours
Fig. 2 Summary of COPD admission care bundle
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tranche. If however, the data extraction is conducted in
‘real time’, they may choose to provide it on a monthly
basis. The data will be compiled and checked for validity
and consistency by a member of the research team.
Level 1 data collection
All sites will report a range of aggregated routine data
including COPD admission rate, COPD re-admission rate
at 28 and 90 days, overall re-admission rate at 28 days, in‐
hospital mortality for COPD admissions, length of stay for
COPD admissions, total bed days for COPD admissions,
total number of COPD patients seen and discharged by
ED and – at implementation sites - the total number of
patients in whom the bundle was used.
Level 2 data collection
In addition to the Level 1 data, Level 2 sites will be re-
quired to provide more detailed, pseudo-anonymised in-
dividual patient-level data including age, sex, ethnicity
and geographical variables. This form of data collection
will also capture non-identifiable clinical information in-
cluding admission month and year; source of admission;
ICD-10 diagnosis codes; Office of Population, Census
and Surveys (OPCS) procedure codes; length of stay -
total and by ward type; discharge destination; healthcare
resource group (HRG) codes; pseudo-anonymised con-
sultant and GP practice codes; re-admission at 28 days
for COPD; re-admission at 28 days for all cause admis-
sions; re-admission at 90 days for COPD; out-patients
appointments; ED appointments; in‐hospital mortality;
90-day mortality including number of days after dis-
charge that death occurred by data linkage to death
registry information and – at implementation sites – the
total number of patients in whom the bundle was used.
Level 2 sites will also report on process measures associ-
ated with the delivery of components of COPD care by
returning information extracted from a randomly se-
lected sample of 140 patient records per site.
Level 3 data collection
In addition to the Level 1 and 2 data, a selection of sites
will form Level 3 case studies and be examined in detail
as regards the process of care bundle implementation,
the context in which the care bundles are delivered, the
impact of the care bundles on staff, patients and carers,
and – where more appropriate – the nature of usual
COPD care. Data collection at this level will be carried
out through non-participant observation and in-depth
interviewing, as well as document analysis. It will be
supported by the use of topic guides and observation
schedules, and conducted by an experienced qualitative
researcher at both implementation and comparator sites.
Information to inform Level 3 analysis will be gathered
throughout the duration of the study, with extended site
visits and post-discharge interviews at 30 and 90 days.
Data management
Standardised templates will be provided to all participat-
ing sites with a request that quantitative data for Level 1
and Level 2 is provided in a format as close as possible
to that template. A named member of staff at each site
will link the different sources of data required at Level 2
(e.g. electronic files, paper-based notes) and supply the
resulting information to the study team in a pseudo-
anonymised format. Each set of data drawn from an in-
dividual patient’s notes will be recorded and linked by a
unique, study-specific identification (ID) number, with
identification keys held only by the relevant trust, to
allow for source data verification as necessary. The
qualitative data collected at Level 3 will be anonymised,
with unique pseudonyms or identifiers assigned to each
participating site or individual, and any identifiable in-
formation removed.
All data - including audio recordings, field notes and
interview transcripts - will be stored at the University of
Bristol, on a secure network drive that it is password
protected, regularly backed-up and only accessible by
COPD discharge care bundle
1) Assess respiratory medications and inhaler technique prior to discharge
2) All patients should receive: 
a. written pack for how to manage further acute exacerbation of their COPD; and
b. discharge pack of ‘emergency’ drugs prior to discharge
3) Assess smoking status by assessing willingness to quit and for those patients indicating a wish for further 
assistance, refer to a stop smoking programme
4) Assess for suitability of pulmonary rehabilitation prior to discharge
5) Organise community follow up within two weeks of discharge from hospital. Where it is not possible to achieve 
this, consideration should be given to establishment of a system whereby patients are contacted by phone 
following their discharge from hospital and are offered the opportunity for support
Fig. 3 Summary of COPD discharge care bundle
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members of the research team. Researchers will use Uni-
versity of Bristol-owned, password-protected laptops to
store study information (e.g. typed field notes), while
working at participating sites and only the researcher
who collected the original data will be able to access in-
formation on their particular laptop. Interviews will be
recorded using an encrypted voice recorder provided by
the University of Bristol and transcription of these data
will be conducted by a suitably qualified and approved
transcription service.
The custodian of the study dataset will be the Chief In-
vestigator (CI). The study database will be designed so as
to protect patient information, in line with GCP guidelines
and the Data Protection Act (DPA) 1998 (http://www.
legislation.gov.uk/ukpga/1998/29/contents). All individ-
uals recruited to the study will be identified only by a
unique patient ID number on any study documentation.
Furthermore, research staff will ensure that all partici-
pants’ anonymity is maintained through protective and
secure handling / storage of information - both within
their own research centre and at the participating sites.
All documentation relating to the study will be access-
ible only to study staff and authorised personnel.
Statistical justification for sample size
The sample size calculation was based on data from
Level 2 sites which will be providing pseudo-anonymised
details of all individual patient-level admissions over a
12-month period pre- and post-implementation of
COPD care bundles. If we have 8 pairs of matched im-
plementation and comparator sites in Level 2, this will
provide a sample of around 10,000 admissions per year.
Assuming an intra-cluster correlation co-efficient (ICC)
of 0.01 and a cluster size of 625 - giving an effect size of
7.25 - there will be greater than 90 % power at the 5 %
significance level to detect a 9 % absolute difference in
the COPD re-admission rate at 28 days, assuming 30 %
of patients are re-admitted in comparator sites.
A random sample of approximately one in five patients
will be selected from Level 2 implementation and com-
parator sites for data on adherence to the care bundles
and on delivery of the components of the care bundles.
The total sample will be in the region of 2240 (16 × 140)
cases. This will provide greater than 90 % power at 5 %
significance to detect a difference in adherence to the care
bundles from 30 to 70 %. In this case, the sample size has
been increased according to a design effect of 29, corre-
sponding to an ICC of 0.02 and a cluster size of 140.
Data analysis
Quantitative analysis of effectiveness data
Level 1 data will be used to calculate the mean change
following the introduction of care bundles for each site
for all outcome measures. This mean change will be
compared between implementer and comparator sites
using ordinary linear regression, with adjustment for the
following measures from the first period: number of
COPD admissions, 28-day re-admission rate, and COPD
mortality rate.
Level 2 data will be used in a series of appropriate re-
gression models - depending on the outcome type - to
compare the difference in change between the imple-
mentation and comparator groups. These models will in-
clude a ‘group x time-period’ interaction term to
estimate the difference in change in outcome between
the implementation and comparator sites before and
after implementation of the care bundles. This approach
will reflect the fact that the samples in the ‘before’ and
‘after’ periods will have captured data from sets of pre-
dominantly different individuals. All models will take ap-
propriate account of the matched design by including
indicator variables to distinguish each pair of sites. This
will accommodate any between-site variation i.e. cluster-
ing, in outcomes. If it proves possible to identify patients
who are admitted several times during the study period,
a sensitivity analysis will be conducted with just the first
of their admissions included, and the primary analysis
elaborated if necessary to accommodate any correlation
in outcome between a single patient’s episodes of care.
Quantitative analysis of cost-effectiveness data
The economic impact of care bundles at Level 1 sites
will be evaluated by using trust-level data to describe the
cost of COPD care per admission for both the imple-
mentation and comparator sites during the ‘before’ and
‘after’ time-periods. Since this analysis will use aggre-
gated trust-level data, a simple unit-costing methodology
will be deployed, based on a weighted average of non-
elective COPD-related HRG codes. This will be used to
estimate the incremental impact of bundles on COPD-
related NHS secondary care costs.
A more detailed economic evaluation for the 90 days fol-
lowing the index admission will be undertaken in Level 2
sites. This will involve the estimation of per-patient
secondary care NHS costs using a more in-depth HRG
unit-costing methodology (www.ncbi.nlm.nih.gov/pubmed/
21905152/) where patient-specific resource use will be
valued using comprehensive, nationally representative
sources e.g. NHS reference costs (https://www.gov.uk/
government/publications/nhs-reference-costs-2014-to-
2015/), the British National Formulary [21] (BNF) and
Unit Costs of Health and Social Care (http://www.
pssru.ac.uk/project-pages/unit-costs/2014/). Information
on procedures and investigations undertaken during an
in-patient stay e.g. x-rays, onward referrals, and drugs pre-
scribed will be collected from a review of medical records
and from routine data. The per-patient cost estimate will
include the cost of admissions and re-admissions during
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the 90-day period. Linked information on 90-day mortality
(including the number of days between discharge and
death) will also be collected. The duration of the interac-
tions between a sub-sample of admitted patients and clin-
ical staff will be recorded in a ‘time and motion’ study at
Level 3 sites in order to provide an estimate of the staff
time involved in treating COPD patients, which will be
costed using the sources described above and used to in-
form the Level 2 cost-effectiveness analysis.
This information on costs and mortality will allow an
estimate of cost-effectiveness to be calculated as a ratio
of the difference in NHS secondary care costs between
intervention and comparator sites to the between-site
differences in 90-day mortality. Uncertainty surrounding
this estimate will be quantified using cost-effectiveness
acceptability curves (CEACs). We will also use deter-
ministic sensitivity analysis where appropriate.
Information on post-discharge resource use will also
be collected from a sub-sample of consented Level 3 pa-
tients during telephone interviews. This information will
be used to provide a descriptive analysis of differences
between types of site in the use of primary care services,
community care, and informal care up to 90 days post-
discharge.
Qualitative analysis
The observational data will be collected in note form,
developed as soon after the period of observation as pos-
sible and then word processed and uploaded into a pro-
prietary qualitative analysis package e.g. NVivo [22]. All
interviews will be digitally recorded, fully transcribed
and anonymised and, similarly, will be uploaded and
stored in readiness for coding and analysis. Both obser-
vational and interview data will then be examined using
a cross-case thematic analysis [23]. This approach will
be used to draw out the key issues in the data, using a
coding framework which will be developed collabora-
tively by members of the research team. This process
will enable both inductive and deductive analysis; focus-
sing on the research questions, and also enabling the
emergence of views and experiences expressed by inter-
viewees. All data will be analysed and interpreted by at
least two qualitative researchers, in order to cross-
reference findings and ensure consistency and clarity.
The analysis will seek to identify similarities and differ-
ences between sites, highlighting aspects that are likely
to be transferable to other hospitals implementing – or
intending to implement – care bundles.
Ethical and regulatory issues
The study received full approval from South West
(Frenchay) Research Ethics Committee on 12 September
2014. As a multi-centre research ethics committee, their
single ethical opinion covers all aspects of the research
and is valid across all participating sites. At the time of
writing, the following sites have agreed to participate:
 Southmead Hospital, Bristol
 James Paget Hospital, Great Yarmouth
 Manchester Royal Infirmary, Manchester
 Worcestershire Royal Hospital, Worcester
 Heartlands Hospital, Birmingham
 Gloucestershire Royal Hospital, Gloucester
 Eastbourne District General Hospital, Eastbourne
 Lister Hospital, Stevenage
 Royal Bolton Hospital, Bolton
 New Cross Hospital, Wolverhampton
 Royal Surrey County Hospital, Guildford
 Bristol Royal Infirmary, Bristol
 Northwick Park Hospital, Harrow
 Leighton Hospital, Crewe
 Poole Hospital, Poole
 Royal Bournemouth General Hospital, Bournemouth
 Kings College Hospital, London
 Bedford Hospital, Bedford
 Peterborough City Hospital, Peterborough
 Southampton General Hospital, Southampton
 South Tyneside District Hospital, South Shields
 Stoke Mandeville Hospital, Aylesbury
 Prince Phillip Hospital, Llanelli
 Wexham Park Hospital, Slough
 Royal Albert Edward Infirmary, Wigan
 University Hospital Coventry, Coventry
 St Mary’s Hospital, Newport
 King George Hospital, Ilford
 Sandwell General Hospital, West Bromwich
 City Hospital, Birmingham
 Torbay District General Hospital, Torquay
 North Devon District Hospital, Barnstaple
 Princess of Wales’ Hospital, Bridgend
 Princess Alexandra Hospital, Harlow
 Luton and Dunstable University Hospital, Luton
 Epsom Hospital, Epsom
All necessary local research governance approvals
will be obtained for each of the above-named sites
prior to the start of data collection. The research
will be conducted in accordance with the principles
of the Declaration of Helsinki (http://www.wma.net/
en/30publications/10policies/b3/), the principles of ICH
good clinical practice (www.ich.org/) and in compli-
ance with all other applicable regulatory requirements
(www.hra.nhs.uk/resources/research-legislation-and-
governance/research-governance-frameworks/). The
study is registered on both the United Kingdom Clinical
Research Network (UKCRN) Portfolio and the Inter-
national Standard Randomised Controlled Trial Number
(ISRCTN) registry.
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Discussion
Despite the fact that COPD is one of the most common
causes of hospital admissions in the UK, there is no clear
evidence as to how it can be most successfully managed
either within or outside the acute setting, in order to im-
prove in-patient care and reduce further re-admissions.
This study will use a controlled before-and-after de-
sign to evaluate the effectiveness of introducing standar-
dised treatment packages i.e. care bundles, for patients
with exacerbated COPD. Trust-level and patient-level
data collected from a sample of hospitals across England
and Wales will provide sufficient power to detect a
meaningful difference in outcomes as regards the clinical
effectiveness of COPD care bundles. In addition, a range
of resource use data will inform a detailed analysis of
their cost-effectiveness. Finally, the nested qualitative
case-studies will offer insight into the processes under-
pinning care bundle implementation as well as the com-
plex array of ‘real life’ factors implicated in looking after
patients with this type of long-term respiratory illness.
Given the number of unplanned hospital admissions
for this patient group and their rate of subsequent re-
admission, it is hoped that the results from this evalu-
ation will make an important and timely contribution to
the existing evidence-base for the benefit of patients, cli-
nicians, managers and policy-makers.
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